Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
about
SCUBE3 is an endogenous TGF-β receptor ligand and regulates the epithelial-mesenchymal transition in lung cancerCaspase-3-mediated cleavage of Akt: involvement of non-consensus sites and influence of phosphorylationOverexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesisQuantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosisHuman kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancerOverexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosisThe Extracellular Matrix in Epithelial Ovarian Cancer - A Piece of a Puzzle.Polymorphic variation of genes in the fibrinolytic system and the risk of ovarian cancer.Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancerUrokinase plasminogen activator: a prognostic marker in multiple types of cancer.Role of CSF-1 in progression of epithelial ovarian cancerPhosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.Soluble E-cadherin: more than a symptom of disease.The hemostatic system and angiogenesis in malignancy.Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic functionMiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progressionType 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study.Plasminogen Activator Inhibitor Type 1 (PAI-1) A15T Gene Polymorphism Is Associated with Prognosis in Patients with EGFR Mutation Positive Pulmonary AdenocarcinomaCirculating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma.Metastasis of ovarian cancer is mediated by kallikrein related peptidases.Bilateral ovarian carcinomas differ in the expression of metastasis-related genesClinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.Involvement of urokinase-type plasminogen activator system in cancer: an overview.Clinical models and biochemical predictors of VTE in lung cancer.Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.Preclinical evaluation of [111 In]MICA-401, an activity-based probe for SPECT imaging of in vivo uPA activity.The plasminogen activator inhibitor system in colon cancer cell lines is influenced by the CO2 pneumoperitoneum.High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination.The effects of epidural anaesthesia and analgesia on natural killer cell cytotoxicity and cytokine response in patients with epithelial ovarian cancer undergoing radical resection.Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3).Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancerDisease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma
P2860
Q24298176-6404C5AB-003D-4003-A219-828491CD3745Q24307737-1D7B9104-487F-4A4A-AF31-A20288992A74Q24317766-E2425A47-4689-4D99-98B9-26BF92938889Q24646799-3FDDF6E0-3B7F-4F5A-8D9A-CD00EA0C5A02Q24648770-EC07D09C-4E44-4D15-95B1-7A4B09A657EFQ31108673-3847151C-74A9-4AE1-978A-A1CC9192CFE4Q33361929-C710691E-BC55-4584-AC16-9EBC5F666A9BQ33467391-967D4EAA-04F9-41D2-9FCE-446D95123012Q33581021-413EDB92-418D-4844-8B2A-40ADC2276473Q33676610-0B179D96-AFED-4FBE-B097-56518CC9C6FCQ33694369-C7873E12-0FF4-4529-BD9B-3D1791B2A7EEQ33725701-D9FDC73A-5594-407A-93E9-7580AA3134C5Q34279705-4403ECF9-B5F7-444B-9AC7-F04EA28A783EQ34425462-5AEB6BA7-1F00-40FF-BD26-D1624A66DF84Q34602948-683523AC-5FC9-4994-A369-F0413DF666B1Q36214635-84680458-119D-4761-B8F7-121AD9EB7AA2Q36486880-96DDA53F-33F6-40A2-8FF7-BBA3E6009F0CQ36577683-13574647-F7A4-434A-AC51-4086CB68C821Q37317112-7639CD3A-C21E-4F6A-8B18-1F1D1BF6E560Q37325023-E107F4E9-E397-40F7-99B7-5732E58C0468Q37390397-AA14F985-62F7-46B6-8B59-D8A76EA1A834Q37480184-B4000084-638A-475A-9818-D2C97C215A09Q37594079-BD5AD26F-5770-44EE-B1EC-296AE19239DAQ37809871-A8033089-4C3F-4CBA-8F4E-2F68F82D510BQ38184632-D9F81507-6622-4E4F-B962-C29D4AAC71ADQ38189275-27F18DD2-4E54-490B-A0E5-9212E51279C8Q38205701-182B9D26-790D-43F4-A814-99679284AEB6Q39115394-F40AD58A-105A-4F66-8A9E-A57881BA640FQ39456396-79E4FCB9-C751-422C-ACE2-1936DC921E66Q39646890-4EAE629F-98B2-47B2-8359-E15A15F79D44Q40784517-6096BFC9-F470-4010-BAE0-16828D686466Q43997799-517E14FC-A1A1-4958-B3CC-9DB50D80A4FAQ47126029-C12341DA-D38F-4C73-B8F8-98A9A18752F7Q48110661-005D1EC7-5375-4E25-B8EA-2529D82D3381Q54038662-A5B7BF2A-E6C8-47A6-AFA2-67AA2F8F9019Q54960825-ED7BE81B-88C9-4194-A6BD-316A79B73EE7Q57940964-3B4C43CC-7ACD-4CBE-8E59-85AE73FB7CAEQ57941761-DA0FB391-659E-4652-B863-AFB411C078CB
P2860
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Prognostic significance of uro ...... ian carcinoma stage FIGO IIIc.
@ast
Prognostic significance of uro ...... ian carcinoma stage FIGO IIIc.
@en
type
label
Prognostic significance of uro ...... ian carcinoma stage FIGO IIIc.
@ast
Prognostic significance of uro ...... ian carcinoma stage FIGO IIIc.
@en
prefLabel
Prognostic significance of uro ...... ian carcinoma stage FIGO IIIc.
@ast
Prognostic significance of uro ...... ian carcinoma stage FIGO IIIc.
@en
P2093
P2860
P356
P1476
Prognostic significance of uro ...... ian carcinoma stage FIGO IIIc.
@en
P2093
Schmalfeldt B
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690278
P407
P577
1999-04-01T00:00:00Z
P5875
P6179
1027741100